Open Label Phase 2 Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated for Waldenström Macroglobulinemia
Latest Information Update: 13 Aug 2024
At a glance
- Drugs Sonrotoclax (Primary) ; Zanubrutinib (Primary)
- Indications Mantle-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- Acronyms WAZABI
- 09 Aug 2024 Status changed from planning to not yet recruiting.
- 18 May 2021 New trial record